TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ACULAR

KETOROLAC TROMETHAMINE
Immunology Approved 1992-11-09
4
Indications
--
Phase 3 Trials
33
Years on Market

Details

Status
Prescription
First Approved
1992-11-09
Routes
OPHTHALMIC
Dosage Forms
SOLUTION/DROPS

Companies

Active Ingredient: KETOROLAC TROMETHAMINE

ACULAR Approval History

Loading approval history...

What ACULAR Treats

3 indications

ACULAR is approved for 3 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Ocular Itching
  • Allergic Conjunctivitis
  • Inflammation
Source: FDA Label

Drugs Similar to ACULAR

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACUVAIL
KETOROLAC TROMETHAMINE
1 shared
AbbVie
Shared indications:
Inflammation
ALREX
LOTEPREDNOL ETABONATE
1 shared
BAUSCH AND LOMB
Shared indications:
Allergic Conjunctivitis
BEPOTASTINE BESILATE
BEPOTASTINE BESILATE
1 shared
SOMERSET THERAPS LLC
Shared indications:
Allergic Conjunctivitis
BEPREVE
BEPOTASTINE BESILATE
1 shared
BAUSCH AND LOMB INC
Shared indications:
Allergic Conjunctivitis
BROMFENAC SODIUM
BROMFENAC SODIUM
1 shared
Lupin
Shared indications:
Inflammation
BROMSITE
BROMFENAC SODIUM
1 shared
Sun Pharma
Shared indications:
Inflammation
BYQLOVI
CLOBETASOL PROPIONATE
1 shared
HARROW EYE
Shared indications:
Inflammation
CARBINOXAMINE MALEATE
CARBINOXAMINE MALEATE
1 shared
MIKART
Shared indications:
Allergic Conjunctivitis
CASPORYN HC
HYDROCORTISONE
1 shared
CASPER PHARMA LLC
Shared indications:
Inflammation
COLOCORT
HYDROCORTISONE
1 shared
CHARTWELL
Shared indications:
Inflammation
DEXTENZA
DEXAMETHASONE
1 shared
OCULAR THERAPEUTIX
Shared indications:
Allergic Conjunctivitis
DIFLUPREDNATE
DIFLUPREDNATE
1 shared
Cipla
Shared indications:
Inflammation
DUREZOL
DIFLUPREDNATE
1 shared
Novartis
Shared indications:
Inflammation
HYDROCORTISONE AND ACETIC ACID
ACETIC ACID, GLACIAL
1 shared
COSETTE
Shared indications:
Inflammation
HYDROCORTISONE IN ABSORBASE
HYDROCORTISONE
1 shared
CMP PHARMA INC
Shared indications:
Inflammation
ILEVRO
NEPAFENAC
1 shared
HARROW EYE
Shared indications:
Inflammation
INDIUM IN 111 OXYQUINOLINE
INDIUM IN-111 OXYQUINOLINE
1 shared
GE HEALTHCARE
Shared indications:
Inflammation
INVELTYS
LOTEPREDNOL ETABONATE
1 shared
Novartis
Shared indications:
Inflammation
KARBINAL ER
CARBINOXAMINE MALEATE
1 shared
AYTU
Shared indications:
Allergic Conjunctivitis
LOTEMAX
LOTEPREDNOL ETABONATE
1 shared
BAUSCH AND LOMB
Shared indications:
Inflammation
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ACULAR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ACULAR is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. ACULAR is a nonsteroidal anti-inflammatory drug (NSAID) indicated for: The temporary relief of ocular itching due to seasonal allergic conjunctivitis. The treatment of inflammation following cataract surgery.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.